Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Research in the area of angiogenesis reported from Columbus Children's Hospital
March 3rd, 2009
According to recent research from the United States, "Approval of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab by the FDA in 2004 reflected the success of this vascular targeting strategy in extending survival in patients with advanced cancers. However, consistent with previous reports that experimental tumors can grow or recur. during VEGF blockade, it has become clear that many patients treated with VEGF inhibitors will ultimately develop progressive disease." "Previous studies have shown that disruption of VEGF signaling in tumors induces remodeling in surviving vessels, and link increased expression of angiopoietin-1 (Ang-1) with this...
Source: Cancer Weekly (2009-03-03)
|
